strengthpeptide
All news
NewsGHK-CuFDAcompounding

GHK-Cu injectable in regulatory limbo as nominators withdraw

GHK-Cu's injectable form sits outside both FDA compounding categories after nominator withdrawal; PCAC will review the peptide before February 2027.

May 27, 2026 · 3 min read

A document on white paper
Photo by Arisa Chattasa on Unsplash

GHK-Cu — the copper-bound peptide widely used for skin, hair, and topical applications — now sits in an awkward regulatory position after its nominations to both FDA compounding categories were withdrawn in April and May 2026. The injectable form is no longer on the Category 2 "Do Not Compound" list (good) but is also not on the Category 1 enforcement-discretion list (not so good for compounding pharmacies). The peptide is scheduled for Pharmacy Compounding Advisory Committee (PCAC) review before the end of February 2027, with topical and non-injectable preparations on a separate path.

The practical effect: compounding pharmacies cannot lawfully prepare injectable GHK-Cu under standard 503A enforcement discretion until further FDA action, but topical GHK-Cu (creams, serums, dermatology applications) faces a different regulatory framework that's been less affected by the recent action.

What happened

A timeline of the relevant actions:

  • April 15, 2026: FDA published notice of upcoming Category 2 removals affecting 12 peptides, with PCAC meeting scheduled July 23–24, 2026 for seven of them.
  • April 22, 2026: Twelve peptides formally removed from Category 2. GHK-Cu's injectable form moved to "Nominated but Withdrawn" status.
  • May 5, 2026: A GHK-Cu nominator clarified that the withdrawal applied only to injectable routes of administration, with the intention to retain the nomination for non-injectable routes.
  • PCAC consultation by Feb 2027: Both forms of GHK-Cu are scheduled for advisory review, separate from the seven peptides going to PCAC in July 2026.

The Frier Levitt analysis explicitly notes that Category 2 removal does not authorize compounding — substances must be on Category 1 or covered by interim enforcement discretion. GHK-Cu injectable sits in neither bucket right now.

Why it matters

GHK-Cu is one of the most widely-used peptides in the strength-peptide and wellness space, with applications across hair restoration, skin aging, and (less prominently) tendon and wound recovery. For the broader frame on GHK-Cu use see the GHK-Cu pillar guide and GHK-Cu topical vs injection.

The regulatory split between injectable and non-injectable forms is unusual and meaningful:

  • Topical GHK-Cu (the dominant cosmetic-industry use case) operates under cosmetic and OTC drug rules — largely unaffected by the recent action. Users can continue to buy and use topical formulations from established cosmetic and supplement companies.
  • Injectable GHK-Cu sits in compliance limbo. Compounding pharmacies that were preparing it have to navigate the new status carefully; research-chemical vendors continue to operate outside the compounding framework anyway.

For users running injectable GHK-Cu protocols (typical strength-peptide community use case for hair, tendon, or systemic effects), the practical impact is mostly on sourcing: compounded injectable GHK-Cu becomes harder to obtain through traditional pharmacy channels until either Category 1 reclassification or the February 2027 PCAC review provides a path forward.

For context on the broader peptide regulatory situation see FDA sets July PCAC review for 7 compounded peptides and FDA PCAC July peptide 503A review.

What to watch

A few markers worth tracking:

  • February 2027 PCAC outcome. If the committee recommends including GHK-Cu on the 503A bulks list (for either route), the regulatory pathway opens. If they don't, GHK-Cu injectable enters a more difficult phase.
  • Cosmetic-industry response. Topical GHK-Cu remains the dominant use case and is unaffected by the current action. Expect continued growth in this segment regardless of the injectable regulatory outcome.
  • Compounding pharmacy positioning. Pharmacies currently preparing GHK-Cu need to navigate the new status; expect some to pause injectable formulations while the regulatory picture clarifies.
  • Research-chemical market dynamics. The compounding-pharmacy regulatory uncertainty often drives users toward research-chemical sourcing as a workaround. Whether GHK-Cu specifically sees this shift remains to be seen.

Sources

Sources